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Abstract
Osteogenesis imperfecta (OI) is a relatively common genetic skeletal disorder with an
estimated frequency of 1 in 20 000 worldwide. The manifestations are diverse and
although individually rare, the several different forms contribute to the production of a
significant number of affected individuals with considerable morbidity and mortality.
During the last decade, there have been extensive molecular investigations into the
etiology of OI and these advances have direct relevance to the medical management
of the disorder, and the purpose of this review is to document the history and evolu-
tion of the nosology of OI. The current nosology, based on molecular concepts, which
are crucial in the identification of genotype-phenotype correlations in persons with OI,
is also outlined. The successive revisions of the nosology and classification of OI have
highlighted the importance of the nomenclature of the condition in order for it to be
recognized by clinicians, scientists and patient advocacy groups. In this way, improved
counseling of patients and individualized, tailored therapeutic approaches based on
the underlying pathophysiology of the individual's type of OI have been facilitated.
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1 | INTRODUCTION
Osteogenesis imperfecta (OI) is a relatively common genetic skeletal
disorder with an estimated frequency of 1 in 20 000 worldwide.1 The
manifestations are diverse and although individually rare, the several
different forms contribute to the production of a significant number
of affected individuals with considerable morbidity and mortality.
The historical accumulation of knowledge concerning OI has been
chronicled in successive editions of Victor McKusick's book “Heritable
Disorders of Connective Tissue”.2In the mid-nineteenth century,
Lobstein (Figure 1) documented the adult form of OI while Vrolik
(Figure 1) described the lethal infantile type. At the beginning of the
20th century, Looser of Heidelberg introduced the terms “OI tarda”
and “OI congenita”. These designations have remained in use in clini-
cal medicine.3
With the introduction of clinical genetics in the 1960s, the auto-
somal dominant (AD) mode of inheritance of the common adult form,
OI-tarda became well established. In OI-congenita, the infantile form
of OI, the consistent normality of the parents and the occasional
recurrence in siblings were suggestive of autosomal recessive
(AR) inheritance.3
In recent years, the classification of OI has been the subject of
extensive discussion and the nosology has evolved with advances in
molecular investigations resulting in the delineation of 20 forms of
OI. This classification embodied the molecular heterogeneity of the
disorder, but the resultant complexity subsequently resulted in confu-
sion in clinical practice. For this reason, the initial phenotypically
based Sillence classification has also been maintained.4It is significant
that in 1979, Sillence et al anticipated the future discovery of consid-
erable heterogeneity.4It is evident that both these approaches are dif-
ferent yet mutually beneficial for the optimal management of persons
with OI.
The complexity of the current categorization became apparent
during a study undertaken in South Africa which documented the oral
and craniofacial manifestations in 64 Black South African persons with
a confirmed diagnosis of osteogenesis imperfecta type III (OI III),
based on the phenotypic manifestations of the disorder.5 Subsequent
molecular investigations resulted in 23 of these individuals being
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further delineated as having the OI XI genotype due to homozygous
mutations in FKBP10.6
During the last decade, extensive molecular investigations into
the etiology of OI have been undertaken and it has emerged that the
molecular determinants are complex. These advances have direct rele-
vance to the medical management of the disorder and the purpose of
this review is to document the history and evolution of the nosology
of OI. The current nosology, based on molecular concepts, which are
crucial in the identification of genotype-phenotype correlations in
persons with OI, is also outlined.
2 | METHODS
An electronic literature search was conducted using PubMed-
MEDLINE, EBSCOhost, World of Science and Google Scholar. We
searched these databases for terms relating to the nosology of OI,
including “Osteogenesis Imperfecta”, “nosology OR nomenclature OR
classification”. The authors used expanded terms and MeSH terms,
where possible, to broaden our search. We then hand searched the
reference lists of relevant studies to find related studies.
Of the 600 titles obtained from our literature search, 179 were
found to be relevant and evaluated for inclusion. We extracted useful
information and collated it to be included in this review. Results were
organized according to chronological order using dated subheadings
for clarity and to reflect the rapid expansion of knowledge over the
last decade.
3 | RESULTS
In 1788, Olaus Jacob Elkman described a family with a condition ter-
med “Osteomalaciae Sistens” in a fragile boned family, which had vari-
ous features associated with OI. In the years to follow over
20 different synonyms or eponyms had been used to describe OI. The
phenotypic heterogeneity contributed to a failure to group these con-
ditions under a single umbrella-term.7
For the sake of chronological organization and clarity, dated sub-
headings have been employed. The increasing pace of the expansion
of knowledge is reflected in the presentation of the years and
decades.
3.1 | 1970's
A group of experts from the field of genetics, pediatrics and pediatric
radiology at a meeting of the European Society of Paediatric Radiol-
ogy, gathered in 1970, in Paris and developed the first “Nomencla-
ture of Constitutional Diseases of Bone”. This document was
referred to as The Paris Nomenclature,8 and it was widely accepted
and published. The purpose of this nomenclature was to standardize
the terminology used to designate the different entities, which com-
prise the group of constitutional or intrinsic diseases of bone. There-
after, the Paris Nomenclature was regularly updated with revision
meetings held in 1977, 1983, 1992, 1997, 2001, 2005, 2010, 2015
and 2019.
The impetus to the understanding of OI was afforded by Sillence
et al4(1979) when subdivision into four main types was proposed. This
numerical classification was based upon an analysis of clinical manifes-
tations and the putative mode of inheritance (Table 1).
The Sillence classification does not reflect the true heterogeneity
of the syndrome, but it remains useful in terms of genetic counseling
and for the prediction of the clinical evolution of the disorder. In this
way, decisions on therapeutic measures are facilitated and optimal
management can be provided for the patients. Persons who receive
details regarding testing, treatment and available choices are thereby,
empowered to make appropriate decisions regarding pregnancy and
their child's health.
F IGURE 1 Jean Frederick Lobstein
1777 to 1835 and Willem Vrolik 1801 to
1863. Google: https://commons.
wikimedia.org (July 2015)
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3.2 | 1980's
By the 1980s, discoveries in collagen biochemistry and later in molec-
ular biology conclusively revealed that the OI-congenita phenotype
usually resulted from new dominant mutations.9,10 At that time the
occasional occurrence in siblings was explained on the basis of
gonadal mosaicism. Most instances of AD OI are caused by mutations
in the COL1A1 and COL1A2 genes. These genes are located on chro-
mosome 17 and 7, respectively, and encode the polypeptide chains of
type I collagen.
A multiexon deletion in a collagen gene, COL1A1 was discovered
in 198311and in 1986, a heterozygous single nucleotide substitution
in COL1A1 was identified as the cause of the form of OI which was
lethal in infants and young children.
3.3 | 1990's
The second official revision of the Paris Nomenclature took place in
1991 at a meeting of the International Working Group on Bone Dys-
plasias in Bad Honnef.12At this time, the classification of OI was orien-
tated on radiographic and morphological criteria and encompassed
the Sillence classification of four main types.
The third official revision of the 1972 Paris Nomenclature of Con-
stitutional Disorders of Bone took place in 1997 in Los Angeles. In this
version of the revised nomenclature, the groups of disorders were
arranged based on etiopathogenetic information concerning the gene
and/or the protein defect. Thirty-two groups of conditions were listed
and OI was included in group 23 which was designated Dysplasias with
Decreased Bone Density. The Sillence classification of the four main
types was maintained and mutations in the COL1A1 and COL1A2
genes were documented.
Following the establishment of the International Society of Skele-
tal Dysplasia (ISDS) in 1999, the revisions were prepared by a group
of experts within the ISDS and the term nomenclature was replaced
with “nosology”.
3.4 | 2000 to 2020
The next official revision took place in 2001 in Oxford and was publi-
shed in 2002.This version included 33 groups of disorders with OI
being placed in group 24. Two new subtypes of OI were included,
namely, Type V, which was characterized by the presence of dis-
located radial heads and hyperplastic callus formation and Type VI,
diagnosed on the bone histology.13
An expanded Sillence classification was published in 2004.14
These authors added OI types V to VII, in which the underlying
genetic defects were initially unknown. Thereafter, following compre-
hensive radiographic, bone morphologic and molecular genetic ana-
lyses, the establishment of an expanded classification was
promulgated. Details are given in Table 2.15
In August 2009, in Boston, the Nosology Committee of the Inter-
national Skeletal Dysplasia Society identified 456 genetic conditions
and placed them into 40 groups, which were defined by molecular,
biochemical and/or radiographic criteria.16 OI was given special atten-
tion at this meeting and was placed in group 25 (Table 3).
Confusion was engendered by the aetiological complexity of the
different forms of OI. Accordingly, the Nosology Committee
suggested that the Sillence classification, which defined and classified
OI according to clinical characteristics and inheritance pattern and not
molecular findings should be retained in clinical practice.16 In this
“Working Nosology” Arabic numerals are used instead of Roman
numerals (Table 4).In the tables below the grouping is compared with
the historic numerical nomenclature but note that the International
Nosology committee recommends Arabic numerals rather than Roman
numerals.
In 2012, the molecular abnormality was identified in the rare AD
OI type 5 in which IFITM5 encodes Interferon-induced transmem-
brane protein 5.17 A further 10% of AR OI has been shown to be cau-
sed by a growing list of mutant genes. These include LEPRE1, PPIB,
PLOD2, FKBP10, SERPINH1, SERPINF1, BMP1, SP7, CRTAP and
TMEM38B.18-24 Mutations in WNT1, which encodes a signaling mole-
cule in osteoblast differentiation and proliferation, have also been
identified.25A homozygous deletion of CREB3L1 was identified in a
family with the progressively deforming OI phenotype has also been
documented.26
With the discovery of each new genetic determinant and follow-
ing further revisions of the nomenclature, the Sillence classification
was expanded to include documented types of OI I to OI XV.27The
categories OI I - OI IV were defined according to the radiological and
clinical presentation of the disorder, whereas OI V to OI XV were
established on the basis of the molecular findings. It is relevant, how-
ever, that there is considerable overlap in the clinical presentation of
OI I to OI IV and OI V to OI XV.28,29
The ninth edition of the Nosology published in 2015 lists 436 dis-
orders in 42 groups and records 364 determinant genes.30 OI remains
in group 25 and the phenotypically based Sillence classification is still
maintained. OI type 5 has been included since it is radiologically dis-
tinct from other forms of OI. The nomenclature used with regard to
OI is that which was recommended in 2011. This data are given in
Table 4.
The number of genes documented in OI type 1 and OI type
2 remains the same as those recorded in 2011. Conversely, the num-
ber of genes involved in OI type 3 has increased from 7 in 2011
TABLE 1 Classification of osteogenesis imperfecta4
Type Clinical features MOI
I Blue sclera, moderate bone fragility AD
II Lethal in the perinatal period AR
III White sclera, severe with progressive
deformity
AR
IV White sclera, variable bone fragility AD
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; MOI,
mode of inheritance.
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to 15, while in OI type 4 the number of listed genes increased
from 5 to 8. The gene and the associated protein in OI type 5 were
identified17(Table 5).
Bruck syndrome (BS) type 1, BS type 2 and osteoporosis-
pseudoglioma syndrome are currently listed as autonomous disorders
in group 2530 and not as “OI, Other types” as previously designated.16
The 2015 Nosology Committee concluded that OI is a
classic skeletal disorder whereby molecular diagnosis depends on
next-generation sequencing, although the prognosis is centered on
phenotypic observations.
By this stage, it was evident that there was a detailed understand-
ing of the molecular events necessary for collagen synthesis (COL1A1
and COL1A2), post-translational processing/modification (CRTAP,
LEPRRE1, PPIB and TMEM38B), folding and crosslinking (SERPINH1,
FKBP10 and PLOD2). Equally, many of the key genes/proteins
involved in the pathogenesis of OI had been elucidated. It was also
TABLE 2 Expanded classification of osteogenesis imperfecta15
Type MOI Severity Fractures BD Stature DI Sclerae Hearing loss
I AD Mild Few to 100's +/− Common Normal or
slightly short




Multiple fractures of ribs, minimal calvarial
mineralization platyspondyly, marked
compression of long bones
Severe Severely short
stature
+ Dark blue −
III AR Severe Thin ribs, platyspondyly, thin fragile bones




Very short + Blue Often
IV AD Moderate
to mild





V AD Moderate Multiple with hypertrophic callous Moderate Variable − N No





VII AR Moderate Multiple Yes Mild short
stature
− N No
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; BD, bone deformity; DI, dentinogenesis imperfecta; MOI, mode of inheritance.
TABLE 3 Category 25: osteogenesis imperfecta and decreased bone density group16 (modified by the author to only include OI and related
conditions)
Name of disorder MOI MIM No. Locus Gene Protein
OI, non-deforming (OI 1) AD 166200 COL1A1, COL1A2 COL1A1: collagen 1 alpha 1 chain
COL1A2: collagen 1 alpha 2 chain
OI, perinatal lethal form (OI 2) AD, AR 166210 COL1A1, COL1A2, CRTAP,
LEPRE1, PPIP
CRTAP: cartilage associated protein





deforming type (OI 3)
AD, AR 259420 COL1A1, COL1A2, CRTAP,
LEPRE1, PPIP, FKBP10,
SERPINH1
FKBP10: FK506 binding protein 10
SERPINH1: serpin peptidase inhibitor,
clade H, member 1
OI, moderate form (OI 4) AD, AR 166220 COL1A1, COL1A2, CRTAP,
FKBP10, SP7
SP7: SP7 transcription factor (osterix)
OI: with calcification of the
interosseous membranes and/ or
hypertrophic callus (OI 5)
AD 610967 Not identified Not identified
OI: other types
Bruck syndrome type I AR 259450 17q21 FKBP10 FK506 binding protein 10
Bruck syndrome type II AR 609220 3q23-24 PLOD2 Procollagen lysyl hydroxylase 2
Osteoporosis-pseudoglioma syndrome AR 259770 11q12-13 LRP5 LDL-receptor related protein 5
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; MOI, mode of inheritance; OI, osteogenesis imperfecta.
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apparent that other non-collagen genes, notably CREB3L1 and SP7,
have roles in osteoblast differentiation.
In order to account for the rapidly growing list of new genes asso-
ciated with OI, Forlino and Marini31 proposed a functional metabolic
classification scheme. This incorporated both clinical and genetic
information for subtyping the condition on the basis of the altered
intracellular or extracellular metabolic pathways (Table 6).
In the latest edition of the Nosology (2019), the pathogenic vari-
ants have been listed for 92% (425/461) of the disorders, which were
included.32Formerly, the percentage of disorders in which the causal
gene was identified was 58% (215/372) in the 2006 revision,33 69%
(316/456) in the 2010 revision,16 and 88% (385/436) in the 2015
revision.30In distinction to preceding revisions, the protein is not
listed, since this can be determined from the gene. The reference list
of clinically recognized entities and their causal genes presented in
this 2019 edition of the Nosology may assist clinicians to attain an
accurate diagnosis for their patients and help enhance research in
skeletal biology.
OI is included in the “Osteogenesis Imperfecta and decreased
bone density group” category 25 (Table 7). Although the phenotypi-
cally based Sillence classification is maintained, the classification of OI
has now expanded up to OI type XX, with the latest addition, muta-
tions in MESD resulting in a progressive deforming OI phenotype.
The PLOD2 and SEC24D genes have been removed as pathologi-
cal variants involved in OI 3, although PLOD2 remains listed as a path-
ological variant in BS type 2. Two new genes, SPARC34 and TENT5A35
have been identified and included as causal genes in OI 3.
Clinical entities, osteoporosis X-linked form and osteoporosis AD
form are also included in group 25.32 In addition to the clinical entity
associated with the PLS3 gene, a recently recognized gene, MBTPS2
which is now diagnosed as OI type XIX, is also implicated in the path-
ogenesis of X-linked Osteoporosis.36The WNT1 and LRP5 genes are
listed as being involved in the pathogenesis of OI type XV and the X-
linked form of AD osteoporosis, respectively.32 The clinical entity, OI
with calvarial doughnut lesions, has been found to result from muta-
tions in SGMS2.37 A further rare type of familial osteoporosis previ-
ously known as OI with jaw lesions, Levin type, was confirmed to
result from mutations in ANO5.38
4 | DISCUSSION
The original classification, which was promulgated by Sillence in 1979
was comprised of four subtypes determined by severity, phenotype
and radiological findings. Thereafter, the evolution in molecular genet-
ics resulted in the discovery of several additional causative genes for
OI. The identification of these novel genes has greatly enhanced the
TABLE 5 Category 25: osteogenesis imperfecta and decreased bone density group,30 (modified by the author to only include OI and related
conditions)
Name of disorder MOI MIM No. Gene Protein
OI type 3 AD, AR 259420 COL1A1, COL1A2, CRTAP,
LEPRE1, PPIP, FKBP10,
SERPINH1




BMP: bone morphogenetic protein 1
PLOD: procollagen lysyl hydroxylase 2
SERPINF1: serpin peptidase inhibitor, clade F, member 1
SP7: SP7 transcription factor (osterix)
WNT1: wingless-type MMTV integration site family, member
1
TMEM38B: transmembrane protein 38B
CREB3L1: OASIS
SEC24D: SEC24-related gene family, member D
OI type 4 AD, AR 166220 COL1A1, COL1A2, CRTAP,
FKBP10, SP7
Refer to OI type 3 above
aWNT1, SERPINF1, PPIB PPIP: peptidylprolyl isomeraseB (cyclophilin B)
OI type 5 AD 610967 aIFITM5 Interferon induced transmembrane protein 5
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; MOI, mode of inheritance; OI, osteogenesis imperfecta.
aThe genes are the latest additions to the 2015 nosology list.
TABLE 4 Recommended nomenclature of osteogenesis
imperfecta (OI) syndromes in order of severity (Nosology Committee
of the International Skeletal Dysplasia Society (ISDS)16
Name of syndrome (recommended
nomenclature of OI syndromes)
Equivalent
numerical types
Classic non-deforming OI with blue sclerae (OI
type 1)
I
Common variable OI with normal sclerae (OI type
4)
IV
OI with calcification in interosseous membranes
(OI type 5)
V
Progressive deforming OI with normal sclerae (OI
type 3)
III
Perinatally lethal OI (OI type 2) II
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understanding of the cellular and biological pathways involved in
OI. However, the rapid pace of these discoveries has resulted in the
publication of multiple classifications, which often times proves chal-
lenging for the clinician to remain abreast of and for the patient to
understand.
This review was conducted in order to document the history and
evolution of the nosology of OI from the four simple types described
in 1979 to the heterogenous 29 types described in 2019. Undoubt-
edly, with advances in molecular and biochemical techniques, this
classification will continue to evolve, and our understanding of the
genotype-phenotype correlations will continue to expand. It is, how-
ever, important that researchers and clinicians are familiar with the
historic nomenclature to better understand and utilize the wealth of
existing literature, which is available.
It is well known that disharmony in osteoblast and osteoclast
activity can result in irregularities in bone density. The understanding
of the molecular basis for bone development and remodeling has
improved significantly in recent years. Several of the identified
disease-causing genes in OI can be classified into one of three major
signaling pathways based on their function. These are collagen I bio-
synthesis, WNT signaling and TGFβ signaling. A majority of the
recently identified pathogenic variations encode for proteins involved
in the post-translational modification of collagen and genetic defects
in osteoblast development. A few disease-causing genes that function
in bone formation is still unclear and independent of the previously
mentioned signaling pathways.
Collagen, in particular collagen type I, is the most abundant and
important organic component of the extracellular matrix which pro-
vides bone with flexibility and strength. Hence, a mutation in one of
the genes responsible for collagen type 1 synthesis and assembly can
be a causative factor in OI. Approximately 90% of the AD forms of OI
which result from mutations in COL1A1 and COL1A2 have been iden-
tified (Figure 2).39
The remaining 10% of the AR types of OI result from mutations
in CRTAP, LEPREI1, PLOD2, CREB3L1, PPIB, SERPINH1, SERPINF1,
FKBP10, TMEM38B, MBTPS2, SPARC and BMP. These genes are
directly or indirectly involved in the collagen type I synthesis and
assembly (Figure 3).40
Apart from genes involved in collagen 1 biosynthesis, mutations
in genes that are involved in other pathways pertinent to bone forma-
tion have also been reported. Mutations in WNT1, a ligand of the
WNT signaling pathway and mutations in Sp7, which encodes osterix,
TABLE 6 Novel gene subtypes of osteogenesis imperfecta. Adapted from Forlino and Marini (2016)31
Type MOI Gene Protein Disease mechanism Skeletal phenotype Associated features
I AD COL1A/2 Collagen type 1, α1/2 Collagen synthesis/
processing
Mild-moderate DI, blue sclera, deafness
II AD Lethal Pulmonary hypoplasia
III AD Severe
IV AD Moderate DI, basilar invagination
V AD IFITM5 Interferon-induced
transmembrane protein 5
Mineralization defect Moderate Hyperplastic callous
formation
VI AR SEPINF1 Pigment epithelium-derived
factor
Mineralization defect Moderate-severe “Fish scale” pattern on iliac
crest biopsies
VII AR CRTAP Cartilage-associated protein Collagen modification Severe-lethal Similar to ΙV, rhizomelia
VIII AR LEPRE1 Leucine proline-enriched
proteoglycan 1/prolyl
3-hydroxylase 1
Collagen modification Severe-lethal Platyspondyly, scoliosis
IX AR PPIB Peptidylprolyl isomerase
B/cyclophilin B
Collagen modification Severe Short stature
X AR SERPINH1 Serpin peptidase inhibitor Chaperone defect collagen
folding
Severe Nephrolithiasis
XI AR FKBP10 FK506 binding protein 65 Chaperone defect collagen
folding
Moderate-severe Congenital contractures
XII AR SP7 Transcription factor 7 Osteoblast development Moderate Midface hypoplasia
XIII AR BMP1 Bone morphogenic protein 1 Collagen synthesis/
processing
Mild-severe Umbilical hernia
XIV AR TNEM38B Transmembrane protein 38 B Collagen modification Severe
XV AR WNT1 Wingless-type member 1 Osteoblast development Moderate-severe Neurological deficits
XVI AR CREB3L1 CAMP responsive element
binding
Osteoblast development Severe
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; DI, dentinogenesis imperfecta; MOI, mode of inheritance.
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an important regulator of mesenchymal stem cell differentiation have
been described.25,41 Finally, OI type V is caused by mutations in the
IFITM5 gene of which the function is still largely unknown.42 Homozy-
gous mutations in WNT1 cause OI types III and XV. Heterozygous
inactivating mutations in WNT1 and heterozygous loss of function
mutations in LRP5 are also indicated in juvenile osteoporosis.43Both
in vivo and in vitro studies have determined that the TGFβ signaling
pathway can influence bone formation and resorption and is an essen-
tial regulator of bone remodeling.44
Using exome sequencing, mutations in PLS3 were identified in a
family with x-linked osteoporosis although the role of PLS3 in bone
remodeling is uncertain. Based on the ability of PLS3 to bind actin and
the expression of PLS3 in osteocytes, a role in mechano-sensing has
been proposed.44Osteocytes induce increased bone formation by
suppressing SOST expression as an adaption to mechanical loading. In
this way, mutations in PLS3 could explain the osteoporotic phenotype
in patients.45
Over the years, the diagnosis of OI has been dependent on the
correlation of clinical data with analysis of relevant radiographs and
biochemical findings. Until recently, molecular genetic confirmation
has often been the concluding step in the diagnostic process. How-
ever, there is considerable overlap in the clinical presentation caused
by the various molecular defects. This implies that the molecular
cause cannot be deduced from the clinical presentation of the
TABLE 7 Category 25: osteogenesis imperfecta and decreased bone Density group,32 (modified by the author to only include OI and related
conditions as well as the additional loci recently reported)
Name of disorder MOI OMIM No. Gene Molecular diagnosis OMIM
OI type 1 AD 166200 COL1A1, COL1A2 OI type I
OI type 2 AD 166200 COL1A1, COL1A2 OI type II
AR 610854 CRTAP OI type VII
AR 610915 LEPRE1 OI type VIII
AR 259440 PPIP OI type IX
ARa 607723a SUCOa SUN1a
OI type 3 AD 259240 COL1A1, COL1A2 OI type III
AR 613982 SERPINF1 OI type VI
AR 610682 CRTAP OI type VII
AR 610915 LEPRE1 OI type VIII
AR 259440 PPIB OI type IX
AR 613848 SERPINH1 OI type X
AR 610968 FKBP10 OI type XI
AR 615066 TMEM38B OI type XIII
AR 112264 BMP1 OI type XIV
AR/AD 615220 WNT1 OI type XV
AR 616229 CREB3L1 OI type XVI
ARa 616507a SPARCa OI type XVIIa
ARa 617952a TENT5A(FAM24A)a OI type XVIIIa
ARa 607783a MESDa OI type XXa
OI type 4 AD 166220 COL1A1, COL1A2 OI type IV
AD 615220 WNT1 OI type XV
AR 610854 CRTAP OI type VII
AR 259440 PPIB OI type IX
AR 610968 FKBP10 OI type XI
AR 606633 SP7 OI type XII
OI type 5 AD 610967 IFITM5 OI type V
Osteoporosis X-linked forma XL 300294 PLS3 OI type XIX
XL MBTPS2
Osteporosis AD forma AD 615220 WNT1 OI type XV
AD LRP5
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; MOI, mode of inheritance; OI, osteogenesis imperfecta.
aThe genes and clinical conditions are the latest additions to the 2019 nosology list.
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patient.46 A notable exception is the distinctive features of AD IFITM-
related OI.17,47 To add to the complexity of attempting to correlate a
molecular diagnosis from a clinical picture, the previously established
relative frequencies of OI types do not appear to hold true to more
recent studies using next-generation sequencing, especially in those
from developing countries.48,49 85% to 90% of OI cases are believed
F IGURE 2 Novel mutations are shown in a schematic representation of the COL1A1 and COL1A2 genes in five patients with OI. In COL1A1:
one missense mutation (p. Gly290Glu), one nonsense mutation (Arg1026Ter), one out-of-frame insertion mutation (p. Leu69GlufsX74) and two
silent mutations. In COL1A2: one missense mutation (p. Gly835Ser) and two silent mutations
F IGURE 3 A schematic representation of the most important signaling pathways regulating bone remodeling which have been identified
through the investigation of monogenic bone disorders such as osteogenesis imperfecta36
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to be due to COL1A1 and COL1A2 defects28,50 and AD IFITM5
defects are the most prevalent non-collagenous form of OI.51 How-
ever, studies conducted in China,52 Malaysia,53 India54 and Brazil42
found between 49% and 73% of OI are due to COL1A1 and COL1A2
defects. There could be several reasons for this, including the relative
distribution of mild, moderate and severe cases within the samples.
Mild and moderate OI tends to be associated with collagen defects
and more severe forms of the disease are associated with non-
collagenous defects.46,55 This discrepancy may also be due to the
superior proficiencies of next-generation sequencing as compared to
Sanger sequencing which was predominantly used in previous studies.
Finally, these findings could truly represent population differences in
the molecular diversity of OI defects. These contradictions between
previous literature and more recent studies indicate that the more we
are learning about OI, the more questions arise.
With the availability and reduction in the cost of next-generation
sequencing, a “genotype first - phenotype later” approach may soon be
the more desired approach implemented. The “genotype first- pheno-
type later” approach has limitations with regard to predicting clinical
outcomes as genotype-phenotype correlations are still not well
established in OI patients. Families with the same pathological variant
have been shown to have heterogenous clinical features and conflicting
findings are common between OI studies. For example, a study of
Swedish OI patients56observed that those without collagen I mutations
do not have dental aberrations, whereas a large study of Italian OI
patients found that 33.3% of patients with these defects have
dentinogenesis imperfecta.57 These are starkly contrasting findings.
New genetic variants are constantly being found that do not relate to
known pathogenic variants, but patients have similar phenotypes. A
study on a Palestinian sample of only 77 OI patients found 11 novel
pathogenic variants in known disease-causing genes and 10% of their
sample had no pathogenic variants in known disease-causing genes.58
Therefore, the more that is understood about genotype-phenotype cor-
relations, the more it will become clinically useful and informative to the
clinician, patients and genetic councilors. It would be advisable that
equal emphasis is placed on both genotyping and phenotyping. The
ever-evolving nosologies remain a useful reference for diagnosis and
genetic counseling. However, the limitations of these reference guides
need to be acknowledged.
In terms of the clinical classification of OI, information concerning
newly discovered genes was initially merged into Sillence types I to
IV, which reflected clinical severity. Type V, which was added, has dis-
tinct radiographic features in comparison to the other types. Difficul-
ties arose with this classification in the provision of accurate genetic
counseling as the condition may change in severity during the lifetime
of an affected person. Thereafter, a functional classification system
was proposed in which it was suggested that the subtype of OI should
be classified based on the underlying pathological mechanism of dis-
ease. In this way, primary collagen structure and function, together
with defects in ossification and mineralization would be grouped
together. The genetic classification, which has now evolved has
expanded upon the original Sillence classification and a new subtype
has been proposed for each defective gene. The genome database,
OMIM, currently lists 20 types of OI, OI types I to XX. This numerical
listing is an amalgamation of the original 5 clinical types with 15 fur-
ther genotypes resulting from dominant, AR or sex-linked inheritance.
It is anticipated that this classification will continually evolve as novel
genes are discovered.
Despite the lack of current consensus as to how to incorporate
the newly discovered genes for OI into a clinically useful system, there
is no doubt that their identification has provided crucial information.
In particular, these novel gene discoveries have expedited investiga-
tions into pathogenic pathways involved in OI and this information
concerning the molecular pathogenesis has resulted in the develop-
ment of specific therapeutic medical interventions.
A regularly updated nosology is also easy to disseminate and
enhances communication between stakeholders, which would other-
wise need to navigate the barrage of the literature that is constantly
produced on the topic. A web-based nosology with all relevant clinical
and molecular information with links to relevant studies and data and
allows for a variety of targeted searches,32 would complement the
published nosology and overcome the limitations of the nosology fall-
ing behind between revisions.59,60One such database is the Osteo-
genesis Imperfecta & Ehlers Danlos syndrome Variant Database
hosted by the University of Leicester (https://www.le.ac.uk/genetics/
collagen/).
5 | CONCLUSION
The understanding of OI has undergone rapid changes over the last
decade and significant genetic concepts have been promulgated. The
successive revisions of the nosology and classification of OI have
highlighted the importance of the nomenclature of the condition in
order for it to be recognized by clinicians, scientists and patient advo-
cacy groups. In this way, improved counseling of patients and individ-
ualized, tailored therapeutic approaches based on the underlying
pathophysiology of the individual's type of OI have been facilitated.
However, the rate of new findings makes it impossible to remain
abreast of new findings. Therefore, a web-based, constantly updated
resource is desirable to complement the widely disseminated and
accepted nosology.
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